Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis

  • Jian Guang LuEmail author
  • Yong Li
  • Liang Li
  • Xuan Kan
Original Paper



Osteopontin (OPN) is a secreted phosphoprotein, which functions as a cell attachment protein and cytokine that signals through two cell adhesion molecules, integrin αvβ3 and CD44, to regulate cancer growth and metastasis. The aim of this study was to investigate the expression of OPN and integrin αv (ITGAV, main receptor of the OPN) in laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC) and correlate the expression quantity with tumor biological behavior.


We have made a tissue microarray of LHSCC and detected the OPN and ITGAV expression by immunohistochemistry in the microarray. The expression quantity of OPN and ITGAV was determined by a professional pathological image processing software (Image-Pro plus 5.02), and the clinical significances of the expression quantity in LHSCC were analyzed.


The expression quantity of OPN and ITGAV in primary and metastatic carcinomas is significantly higher than in normal tissues. The expression of OPN and ITGAV in the well-differentiated group is significantly lower than in moderately and poorly differentiated group; the expression quantity of OPN and ITGAV in group with lymph node metastasis is significantly higher than in group without lymph node metastasis.


The expression of OPN and ITGAV was significantly influenced to the differentiation and metastasis of the LHSCC. Overexpression of the OPN and ITGAV may have contributed to invasion and metastasis of the LHSCC, and therefore, OPN and ITGAV may have value as a target for chemotherapy in LHSCC treatment.


Laryngeal neoplasms Hypopharyngeal neoplasms Osteopontin Integrin αv Differentiation Metastasis 


Conflict of interest



  1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMedGoogle Scholar
  2. Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M (2005) Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and evasiveness. Clin Cancer Res 11(22):8019–8027PubMedCrossRefGoogle Scholar
  3. Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancers. Lung Cancer 15:311–323PubMedCrossRefGoogle Scholar
  4. Coppola D, Szabo M, Boulware D (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRefGoogle Scholar
  5. Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723–749PubMedCrossRefGoogle Scholar
  6. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632PubMedCrossRefGoogle Scholar
  7. Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D (1995) Engagement of the osteoclast integrin αvβ3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology 136:2984–2992PubMedCrossRefGoogle Scholar
  8. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW (1995) A biochemical characterization of the binding of osteopontin to integrins αvβ1 and αvβ5. J Biol Chem 270:26232–26238PubMedCrossRefGoogle Scholar
  9. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219–226PubMedGoogle Scholar
  10. Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T (2002) Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem 84:420–432PubMedCrossRefGoogle Scholar
  11. Kumar CC (1998) Signaling by integrin receptors. Oncogene 17:1365–1373PubMedCrossRefGoogle Scholar
  12. Licitra L, Bernier J, Grandi C (2003) Cancer of the larynx. Crit Rev Oncol Hematol l47:65–80CrossRefGoogle Scholar
  13. Medico E, Gentile A, Lo CC, Williams TA, Gambarotta G, Trusolino L, Comoglio PM (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61:5861–5868PubMedGoogle Scholar
  14. Oates AJ, Barraclough R, Rudland PS (1997) The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17:1–15PubMedGoogle Scholar
  15. Rosai J, Carcangiu ML, DeLellis RA (1992) Atlas of tumor pathology—tumors of the larynx, 3rd series. Armed Force Institute of Pathology, WashingtonGoogle Scholar
  16. Ruoslahti E (1991) Integrins. J Clin Invest 87:1–5PubMedCrossRefGoogle Scholar
  17. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Perruzzi CA, Detmar M (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the ß3 integrin, osteopontin, and thrombin. Am J Pathol 149:293–305PubMedGoogle Scholar
  18. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMedGoogle Scholar
  19. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mamm Gland Biol Neoplasia 6:419–429CrossRefGoogle Scholar
  20. Tuck AB, Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578–584PubMedGoogle Scholar
  21. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475PubMedCrossRefGoogle Scholar
  22. Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8(5):724–730PubMedCrossRefGoogle Scholar
  23. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMedGoogle Scholar
  24. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC, Smith JW (1998) αv integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 16:50–61PubMedCrossRefGoogle Scholar
  25. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274:36328–36334PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Otolaryngology/Head and Neck SurgerySecond Affiliated Hospital of Harbin Medical UniversityHarbin CityPeople’s Republic of China

Personalised recommendations